Phase II data for Visudyne

Novartis (NVS) and QLT (QLTI; TSE:QLT) said that two-year data from a placebo-controlled Phase IIIb trial of Visudyne therapy in 339 patients with subfoveal choroidal neovascularization

Read the full 268 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE